NCT03418038 2026-03-18
Ascorbic Acid and Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma, CCUS, and Chronic Myelomonocytic Leukemia
Mayo Clinic
Phase 2 Recruiting
Clinical Trials
25 trialsNCT03615664 2025-01-16
BURGUND
Polish Lymphoma Research Group
Phase 2 Completed
NCT00574496 2023-09-28
Combination Chemotherapy Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or High-Risk Primary Refractory Hodgkin Lymphoma
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT00377052 2023-08-04
Bortezomib and Gemcitabine in Treating Patients With Relapsed Mantle Cell Lymphoma
Canadian Cancer Trials Group
Phase 2 Completed
NCT00014209 2020-04-09
Combination Chemotherapy in Hodgkin's Disease or Non-Hodgkin's Lymphoma Not Responding to Previous Treatment
Canadian Cancer Trials Group
Phase 2 Completed
NCT02918747 2020-01-28
PEG-ASP+Gemoxd vs. PEG-ASP+CHOP as First-line Chemotherapy to Treatment NK/T-cell Lymphoma With Early Stage
Hunan Cancer Hospital
Phase 2 Unknown
NCT01200329 2019-12-16
High-Dose Gemcitabine, Busulfan and Melphalan for Patients With Refactory Hodgkin's Disease
M.D. Anderson Cancer Center
Phase 2 Completed
NCT00003397 2019-11-04
Peripheral Stem Cell Transplantation Plus Combination Chemotherapy and Monoclonal Antibody Therapy in Treating Patients With Non-Hodgkin's Lymphoma
University of Maryland, Baltimore
Phase 2 Completed
NCT03151876 2018-07-18
Chidamide Combined With Clad/Gem/Bu With AutoSCT in R/R Diffuse Large B Cell Lymphoma
Sichuan University
Phase 2 Unknown
NCT00388349 2017-06-14
Gemcitabine and Hodgkin's Disease Chemotherapy Followed by Peripheral Blood Stem Cell Rescue for Hodgkin's Disease
Stanford University
Phase 2 Completed
NCT00881387 2016-12-15
Rituximab, Gemcitabine, and Vinorelbine in Treating Patients With Hodgkin Lymphoma That Has Relapsed or Not Responded to Treatment
University of Miami
Phase 2 Withdrawn
NCT00086801 2016-07-01
Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage I or Stage II Hodgkin's Lymphoma
Alliance for Clinical Trials in Oncology
Phase 2 Completed
NCT00262860 2016-05-09
Bortezomib and Gemcitabine Hydrochloride in Treating Patients With Relapsed or Refractory Hodgkin's Lymphoma
University of Rochester
Phase 2 Completed
NCT00280878 2016-01-15
Rituximab in Combination With Outpatient Therapy for CD20+ Lymphoma
Bayside Health
Phase 2 Completed
NCT00163748 2016-01-08
Efficacy and Treatment Related Toxicity Study of a New Regimen for Lymphoma
Bayside Health
Phase 2 Completed
NCT00163761 2016-01-08
Efficacy Study of Outpatient Therapy for Lymphoma
Bayside Health
Phase 2 Completed
NCT00971763 2014-12-04
Gemcitabine Hydrochloride, Cyclophosphamide, Vincristine Sulfate, Prednisolone, and Rituximab in Treating Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma
University College, London
Phase 2 Completed
NCT00660231 2014-12-03
GemBex
University College, London
Phase 2 Completed
NCT00109928 2014-10-01
S0350 Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II, Stage III, or Stage IV Peripheral T-Cell Non-Hodgkin's Lymphoma
SWOG Cancer Research Network
Phase 2 Completed
NCT01884441 2014-01-29
Bendamustine, Gemcitabine and Vinorelbine (BeGEV) as Induction Therapy in Relapsed/Refractory Hodgkin's Lymphoma Patients
Istituto Clinico Humanitas
Phase 2 Unknown
NCT01307592 2014-01-10
Gemcitabine Hydrochloride, Rituximab, Oxaliplatin, and Lenalidomide in Treating Patients With Relapsed or Refractory, Aggressive Non-Hodgkin Lymphoma
National Cancer Institute (NCI)
Phase 2 Unknown
NCT00070304 2013-07-26
Gemcitabine and Vinorelbine in Treating Young Patients With Recurrent or Refractory Hodgkin's Lymphoma
Children's Oncology Group
Phase 2 Completed
NCT00079261 2012-09-24
Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone With or Without Gemcitabine in Treating Patients With Previously Untreated Aggressive Non-Hodgkin's Lymphoma
European Organisation for Research and Treatment of Cancer - EORTC
Phase 2 Completed
NCT00234026 2012-06-05
Gemcitabine in Treating Patients With Newly Diagnosed, Relapsed, or Chemotherapy-Resistant Mantle Cell Lymphoma
Swiss Cancer Institute
Phase 2 Completed
NCT00216164 2011-05-02
Rituximab and Gemcitabine for Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Hoosier Cancer Research Network
Phase 2 Terminated